Published in Obesity and Diabetes Week, November 3rd, 2003
The patents cover compounds that are inhibitors of imidazoline receptors. Drugs that target these receptors are potential treatments for diseases such as Alzheimer, type 2 diabetes, hypertension, and depression. Immtech has exclusive licensing rights to the compounds developed by the UNC-led consortium.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.